New drug cocktail aims to tame deadly transplant complication

NCT ID NCT02891603

Completed Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding pacritinib to standard immune-suppressing drugs (sirolimus and tacrolimus) could prevent graft-versus-host disease (GVHD) in 40 patients receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the recipient's body. The trial measured immune cell activity and tracked how many patients developed GVHD. Results could lead to safer transplant procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pacritinib and Sirolimus
What this could lead to: If successful, this approach could reduce the risk of serious GVHD after stem cell transplants, making the procedure safer for patients.
What could go wrong: This is an early-phase trial with only 40 participants, so results may not apply to everyone. The drug combo also carries risks like infection or side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia B-cell chronic lymphocytic leukemia chronic myelogenous leukemia, BCR-ABL1 positive Hodgkins lymphoma myelodysplastic syndrome myeloproliferative neoplasm non-Hodgkin lymphoma graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT VS HOST DISEASE GVHD

Contacts and locations

Locations

H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States
University of Minnesota

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.